Homocysteine (Hcy) is a sulfur‑containing amino acid formed during methionine metabolism and plays an important role in the body’s methylation cycle. Although it is a normal metabolic intermediate, elevated circulating levels have been associated with increased risk of cardiovascular disease, neurological disorders, and metabolic dysfunction. Elevated homocysteine has been identified as an independent predictor of cardiovascular and all-cause mortality, making it a clinically relevant biomarker for assessing long-term disease risk.

One recent analysis revealed that elevated homocysteine levels were associated with a 66% increase in coronary heart disease risk and a 68% increase in cardiovascular mortality. 

Homocysteine levels are tightly regulated through two primary metabolic pathways: remethylation and transsulfuration. In the remethylation pathway, homocysteine is converted back into methionine using nutrients such as folate and vitamin B12, while in the transsulfuration pathway, it is converted into the amino acid cysteine through reactions requiring vitamin B6. These pathways depend heavily on adequate intake and bioavailability of B‑vitamins, as well as methyl donors such as trimethylglycine (TMG), also known as betaine. When these pathways are disrupted, homocysteine levels may increase due to factors such as B‑vitamin deficiencies, smoking, alcohol consumption, genetic polymorphisms such as MTHFR variants, aging, or certain medications. Elevated homocysteine may also contribute to oxidative stress and inflammation through increased production of reactive oxygen species and formation of reactive metabolites such as homocysteine thiolactone.

A recent case report examined seven patients with elevated homocysteine who were receiving care at a functional medicine clinic. Baseline homocysteine levels ranged from 10.5 to 15.3 µmol/L (laboratory reference range typically <11.4 µmol/L). Although the patients presented with different clinical concerns, several shared risk factors were observed across the group. Patients varied in age and medical history, including diagnoses such as Hashimoto’s thyroiditis, osteoporosis, chronic gastrointestinal symptoms, dyslipidemia, autoimmune skin disease, and fatigue. Lifestyle factors associated with elevated homocysteine were also present in several cases, including alcohol consumption, smoking, and limited physical activity. Despite these differences, all participants received the same nutritional intervention targeting homocysteine metabolism.

During the intervention, participants were given a targeted nutraceutical approach designed to support methylation and homocysteine metabolism. The protocol included nutrients known to participate in the remethylation and transsulfuration pathways, including riboflavin (as riboflavin‑5‑phosphate), vitamin B6 (as pyridoxal‑5‑phosphate), folate (as 5‑methyltetrahydrofolate), vitamin B12 (as methylcobalamin), trimethylglycine (TMG), and L‑serine. Together, these nutrients function as cofactors and methyl donors that support enzymatic reactions that convert homocysteine back into methionine or direct it toward cysteine synthesis, helping to maintain healthy homocysteine metabolism.

Following supplementation, all seven patients experienced significant reductions in homocysteine levels over follow-up periods ranging from three to six months.

Homocysteine reductions observed in the seven cases included:

• 10.5 → 8.1 µmol/L (22.9% reduction)
• 11.7 → 9.0 µmol/L (23.1% reduction)
• 10.7 → 9.7 µmol/L (9.4% reduction)
• 12.6 → 10.1 µmol/L (19.8% reduction)
• 13.7 → 10.5 µmol/L (23.4% reduction)
• 15.0 → 10.8 µmol/L (28.0% reduction)
• 15.3 → 8.2 µmol/L (46.4% reduction)

Across all participants, the intervention resulted in an average reduction of approximately 3.3 µmol/L, corresponding to a 24.7% decrease in homocysteine levels. Although patients also received individualized dietary and lifestyle recommendations based on their clinical presentation, each case included the same targeted nutraceutical protocol designed to support homocysteine metabolism. These findings highlight the potential role of nutritional support for methylation pathways in helping regulate homocysteine levels. 

While elevated homocysteine is widely recognized as a biomarker associated with cardiovascular and metabolic risk, there is currently no standardized pharmaceutical therapy specifically designed to address it. As with any case report, these findings reflect individual responses and cannot be generalized to broader populations. However, the consistent reductions observed across seven patients suggest that targeted nutritional approaches may play a supportive role in maintaining healthy homocysteine levels. Further controlled studies are needed to better understand the potential clinical applications of this approach.

Learn more about healthy homocysteine levels and methylation:

Methylation 101: What Is It and Why Does It Matter For Health? 

Supporting Mental Health with Healthy Homocysteine

Methylated Folate for Normal Homocysteine Status 

Exploring the Spectrum of ‘Normal’ B12 Levels: An Observational Study in Neurological Health 

By Jesse Martin, MS